• If you are wondering whether Bausch Health Companies at around US$6.79 is a bargain or a value trap, you are not alone. It is worth slowing down and looking closely at what the current price might be implying.
• The stock has seen a 9.5% decline over the last 7 days, a 1.3% decline over the last 30 days, a 5.8% decline year to date, and a 9.1% decline over the last year, following a much larger 74.3% decline over the last 5 years. This naturally raises questions about both risk and potential upside from here.
• These moves sit against a backdrop of continuing attention on the broader pharmaceuticals and biotech space and ongoing scrutiny of companies that carry meaningful debt or are working through product and portfolio shifts. For Bausch Health Companies, this context helps explain why investors are so focused on what the current share price might be saying about future expectations and balance sheet resilience.
• Right now Bausch Health Companies scores 5 out of 6 on our valuation checks for being undervalued, giving it a valuation score of 5/6. We will look at what different methods like discounted cash flow, multiples and peer comparisons suggest about that figure before closing with a way to look at valuation that brings all these pieces together.

Approach 1: Bausch Health Companies Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimated future cash flows and discounts them back to what they might be worth today, aiming to arrive at an intrinsic value per share.

For Bausch Health Companies, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about US$1.14b. Analyst inputs and subsequent extrapolations generate a series of projected free cash flows, including an estimate of about US$2.37b in 2030, with intermediate years such as 2026 to 2030 ranging between roughly US$2.31b and US$3.01b before discounting.

After discounting these projected cash flows back to today, the DCF output indicates an estimated intrinsic value of about US$66.77 per share. Compared with the recent share price of around US$6.79, this indicates an intrinsic discount of about 89.8%, based on this model alone.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Bausch Health Companies is undervalued by 89.8%. Track this in your watchlist or portfolio, or discover 874 more undervalued stocks based on cash flows.

Approach 2: Bausch Health Companies Price vs Earnings

For a profitable business, the P/E ratio is a useful way to think about value because it links what you pay directly to the earnings the company is currently generating. Higher growth expectations and lower perceived risk usually justify a higher P/E, while slower growth or higher risk tend to support a lower, more cautious P/E.

Bausch Health Companies is trading on a P/E of about 6.95x. That sits well below the Pharmaceuticals industry average of about 20.49x and also below the broader peer group average of roughly 33.31x. On simple comparisons, the stock appears inexpensive relative to both its industry and peers.

Simply Wall St’s Fair Ratio for Bausch Health Companies is 18.16x. This is a proprietary estimate of what a reasonable P/E might be given the company’s earnings profile, industry, profit margins, market value and specific risks. Because it incorporates these factors, the Fair Ratio can give a more tailored view than a basic industry or peer comparison. Comparing this Fair Ratio with the current 6.95x indicates that the shares are trading below what this framework would view as a fair P/E.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1444 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your Bausch Health Companies Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. These are simply your own story about a company, tied directly to the numbers you think are reasonable for its future revenue, earnings and margins.

A Narrative connects three pieces: your view of Bausch Health Companies as a business, the forecast that flows from that view, and the fair value that drops out of those assumptions, so you are not just looking at ratios in isolation.

On Simply Wall St, millions of investors create and share these Narratives on the Community page. They then compare the Fair Value from their Narrative with the current share price to help decide whether the stock looks attractive, fully priced or expensive given their own assumptions.

Because Narratives update when new information such as earnings or news is added to the platform, your fair value view can change automatically as the story changes. Different investors can still disagree; for example, one Bausch Health Companies Narrative might assume very cautious margins and arrive at a low fair value, while another assumes more resilient cash flows and arrives at a much higher fair value.

Do you think there's more to the story for Bausch Health Companies? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.